

**THERATECHNOLOGIES TO ANNOUNCE FINANCIAL RESULTS  
FOR ITS FIRST QUARTER FISCAL 2021**

News Release

**Montreal, Canada – April 1, 2021** - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the first quarter of fiscal 2021 ended February 28, 2021 on Wednesday, April 14, 2021.

A conference call will be held on April 14, 2021 at 8:30 a.m. (ET) to discuss the results. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a “listen-only” basis.

The conference call can be accessed by dialing 1-844-400-1697 (toll free) or 1-703-736-7400 (International). The conference call will also be accessible via webcast at <https://edge.media-server.com/mmc/p/yiqvgmdq>. Audio replay of the conference call will be available on the same day starting at 11:30 a.m. (ET) until April 21, 2021, by dialing 1-855-859-2056 (North America) or 1-404-537-3406 (International) and by entering the access code: 7982427. The audio replay is also available until April 14, 2022 on <https://edge.media-server.com/mmc/p/yiqvgmdq>.

**About Theratechnologies**

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at [www.theratech.com](http://www.theratech.com), on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov](http://www.sec.gov).

-30-

**For media inquiries:**

Denis Boucher  
Vice President, Communications and Corporate Affairs  
514-336-7800

**For investor inquiries:**

Leah Gibson  
Senior Director, Investor Relations  
617-356-1009  
[ir@theratech.com](mailto:ir@theratech.com)